← Leaderboards
Sabine M Brouxhon
University Of Rochester
$3,578,999
Attributed
$3,578,999
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $756.3K · FY2008–22$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,578,999 · 4
By mechanism
R01$2,138,109 · 1
R21$785,475 · 2
K08$655,415 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Alice P Pentland$5,682,476
- Joseph D. Rosenblatt$6,445,612
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorCellsMediatingE-CadherinMouse ModelPathway InteractionsMalignant NeoplasmsIn VitroOncogenicProteinsEndocytosisInhibitor/AntagonistIn VivoTumorigenicGrantNeoplastic CellClinical TrialsReceptor SignalingSignal TransductionExhibitsDown-RegulationMonoclonal AntibodiesMouse Mammary Tumor VirusAntibodies
Grant awards (21)
sEcad as a novel target and therapy for IGF-1R expressing tumors$398,750
R01 · FY2022 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$357,558
R01 · FY2022 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$1
R01 · FY2021 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$333,940
R01 · FY2019 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$344,269
R01 · FY2018 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$1
R01 · FY2017 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$344,388
R01 · FY2016 · CA · contact PI
A novel multi-targeted therapy for breast cancer resistance$154,204
R21 · FY2016 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$353,466
R01 · FY2015 · CA · contact PI
A novel multi-targeted therapy for breast cancer resistance$189,936
R21 · FY2015 · CA · contact PI
A novel multi-targeted therapy for breast cancer resistance$16,254
R21 · FY2015 · CA · contact PI
sEcad as a novel target and therapy for IGF-1R expressing tumors$5,736
R01 · FY2015 · CA · contact PI
PG's and Keratinocyte Adhesion$131,083
K08 · FY2013 · CA · contact PI
PG's and Keratinocyte Adhesion$131,083
K08 · FY2012 · CA · contact PI
PG's and Keratinocyte Adhesion$131,083
K08 · FY2011 · CA · contact PI
The role of E-cadherin in photocarcinogenesis$194,081
R21 · FY2010 · ES · contact PI
PG's and Keratinocyte Adhesion$131,083
K08 · FY2010 · CA · contact PI
The role of E-cadherin in photocarcinogenesis$183,054
R21 · FY2008 · ES · contact PI
PG's and Keratinocyte Adhesion$106,696
K08 · FY2008 · CA · contact PI
The role of E-cadherin in photocarcinogenesis$47,946
R21 · FY2008 · ES · contact PI
PG's and Keratinocyte Adhesion$24,387
K08 · FY2008 · CA · contact PI